Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Good Neighbors Make Good Regulatory Science Centers, FDA Decides

Executive Summary

Georgetown, Maryland gain CERSI grants in part because of their proximity to agency staff.

You may also be interested in...



US FDA's CDER Creates Quantitative Medicine Center Of Excellence; Job Includes AI Oversight

The group will coordinate quantitative medicine issues throughout the FDA's Center for Drug Evaluation and Research to help streamline drug development.

Califf Lowering FDA Drawbridge To Work With External Expertise

In an exclusive interview, new commissioner Robert Califf says FDA will tap knowledge beyond its walls, without compromising agency independence.

Califf Lowering FDA Drawbridge To Work With External Expertise

In Pink Sheet's exclusive interview, new commissioner says FDA will tap knowledge beyond its walls, without compromising agency independence.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel